Pharma giant Bayer Pharmaceuticals and Zydus Lifesciences have ended their 50:50 joint venture called Bayer Zydus Pharma Private Limited (BZPPL). Bayer has acquired the remaining 25% stake from Zydus to gain full ownership of the entity.
The joint venture was formed in 2011 to leverage the strengths of both companies in marketing and selling pharmaceutical products in the fast-growing Indian market. Zydus brought its extensive Indian marketing expertise, wide distribution network, and deep industry connections. Bayer provided its global commercialization capabilities and innovation pipeline.
During its 12+ year run, BZPPL made inroads across major therapeutic areas such as cardiovascular, diabetes, women’s health, ophthalmology and oncology in India. The collaboration allowed the companies to combine Zydus’ local market knowledge with Bayer’s R&D and product launch capabilities to better serve Indian patients.
Shweta Rai, Managing Director of Bayer’s Pharmaceuticals division in India, praised Zydus as “a formidable partner” in addressing unmet healthcare needs. She stated that as Bayer takes full ownership, it remains committed to India and its mission of “Health for All, Hunger for None.” Building on over a decade of progress, Bayer aims to continue providing innovative health solutions.
The termination of the JV is in line with pre-agreed terms between the partners.
Last updated: December 26th, 2025
